Form 4: Astera Labs Director Sells $24.9M in Stock

Astera Labs Director Manuel Alba executed pre-planned sales of 150,000 common shares totaling approximately $24.9 million.

Summary

• Manuel Alba, a Director of Astera Labs, Inc., sold a total of 150,000 shares of common stock.
• These sales occurred on December 1, 2025, through multiple transactions.
• The shares were sold at weighted average prices ranging from $153.7961 to $172.575 per share, totaling approximately $24.9 million.
• The transactions were executed automatically under a Rule 10b5-1 trading plan adopted on May 29, 2025.
• Following these transactions, Alba's indirect beneficial ownership through the Alba Trust decreased to 1,574,498 shares.
• Alba also indirectly beneficially owns 385,863 shares through Casa Alameda 2007, LLC, 5,000 shares through his spouse, and directly owns 2,351 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director selling shares can sometimes be seen negatively, the disclosure that these sales were pre-planned under a Rule 10b5-1 plan mitigates concerns about immediate insider sentiment regarding the company's prospects. It represents a planned liquidity event rather than a reactive sale.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a systematic approach to liquidity rather than a reaction to new, negative information.

Negatives

• A significant volume of shares (150,000) was sold by a director, which could be perceived as a reduction in insider conviction, even if pre-planned.

Future Outlook

NA

Management Comments

• The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2025.
• The Reporting Person disclaims beneficial ownership of these securities [held by Alba Trust and Casa Alameda 2007, LLC], except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This is a standard insider trading disclosure (Form 4) and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual director's portfolio management.

Related Party Transactions

• Sales of common stock by Manuel Alba, a Director, through the Alba Trust, of which he and his spouse are co-trustees.
• Beneficial ownership of shares through Casa Alameda 2007, LLC, of which the Reporting Person is a manager.
• Beneficial ownership of shares by spouse.

Stakeholder Impact

• Shareholders may interpret the director's sales as a signal, though the 10b5-1 plan suggests it is not based on new, non-public information. The sales represent a reduction in insider holdings.

Key Dates

Recommendation

The filing details pre-planned insider sales by a director under a Rule 10b5-1 plan. Such sales are typically for personal financial planning and do not necessarily reflect a change in the director's outlook on the company's future performance. While a large volume of shares was sold, the pre-scheduled nature of the transactions prevents a strong 'sell' signal. Without additional company-specific news or financial updates, this Form 4 alone does not warrant a change from a 'hold' position.

Keywords

Astera Labs, ALAB, Insider Trading, Form 4, Stock Sale, Director, Manuel Alba, Rule 10b5-1, Equity Sales, Beneficial Ownership